Related references
Note: Only part of the references are listed.Adherence With Oral Anticancer Therapies: Clinical Trial vs Real-world Experiences With a Focus on Prostate Cancer
Celestia S. Higano et al.
JOURNAL OF UROLOGY (2023)
Decreased sensitivity of cyclin-dependent kinase 4/6 inhibitors, palbociclib and abemaciclib to canine lymphoma cells with high p16 protein expression and low retinoblastoma protein phosphorylation
Leni Maylina et al.
JOURNAL OF VETERINARY MEDICAL SCIENCE (2023)
Effects of ABCB1 and ABCG2 Polymorphisms on the Pharmacokinetics of Abemaciclib Metabolites (M2, M20, M18)
Akimitsu Maeda et al.
ANTICANCER RESEARCH (2023)
Adherence to oral anticancer hormonal therapy in breast cancer patients and its relationship with treatment satisfaction: an important insight from a developing country
Amer A. Koni et al.
BMC WOMENS HEALTH (2023)
Effects of the Moderate CYP3A4 Inhibitor Erythromycin on the Pharmacokinetics of Palbociclib: A Randomized Crossover Trial in Patients With Breast Cancer
Laura Molenaar-Kuijsten et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2022)
ABCB1 and ABCG2 limit brain penetration and, together with CYP3A4, total plasma exposure of abemaciclib and its active metabolites
Alejandra Martinez-Chavez et al.
PHARMACOLOGICAL RESEARCH (2022)
Combination of Abemaciclib following Eribulin Overcomes Palbociclib-Resistant Breast Cancer by Inhibiting the G2/M Cell Cycle Phase
Kamal Pandey et al.
CANCERS (2022)
Combination of ZEN-3694 with CDK4/6 inhibitors reverses acquired resistance to CDK4/6 inhibitors in ER-positive breast cancer
Olesya A. Kharenko et al.
CANCER GENE THERAPY (2022)
Effects of ABCB1 and ABCG2 polymorphisms on the pharmacokinetics of abemaciclib
Akimitsu Maeda et al.
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY (2022)
The Resistance of Cancer Cells to Palbociclib, a Cyclin-Dependent Kinase 4/6 Inhibitor, is Mediated by the ABCB1 Transporter
Han Fu et al.
FRONTIERS IN PHARMACOLOGY (2022)
Breast Cancer, Version 3.2022
William J. Gradishar et al.
JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK (2022)
CDK4/6 inhibitor resistance: A bibliometric analysis
Jiayuecheng Pang et al.
FRONTIERS IN ONCOLOGY (2022)
Molecular dynamics simulation and in vitro evaluation of herb-drug interactions involving dietary polyphenols and CDK inhibitors in breast cancer chemotherapy
Prajakta H. Patil et al.
PHYTOTHERAPY RESEARCH (2022)
OPTIMAL Breast Cancer Care: Effect of an Outpatient Pharmacy Team to Improve Management and Adherence to Oral Cancer Treatment
Jasmine V. Patel et al.
JCO Oncology Practice (2022)
An Integrated Pharmacological Counselling Approach to Guide Decision-Making in the Treatment with CDK4/6 Inhibitors for Metastatic Breast Cancer
Rossana Roncato et al.
FRONTIERS IN PHARMACOLOGY (2022)
Chinese Society of Clinical Oncology Breast Cancer (CSCO BC) guidelines in 2022: stratification and classification
Jianbin Li et al.
CANCER BIOLOGY & MEDICINE (2022)
Intrinsic and acquired resistance to CDK4/6 inhibitors and potential overcoming strategies
Xia-qing Xu et al.
ACTA PHARMACOLOGICA SINICA (2021)
Severe rhabdomyolysis induced by possible drug-drug interaction between Ribociclib and Simvastatin
Caroline Streicher et al.
JOURNAL OF ONCOLOGY PHARMACY PRACTICE (2021)
RON signalling promotes therapeutic resistance in ESR1 mutant breast cancer
Derek Dustin et al.
BRITISH JOURNAL OF CANCER (2021)
HDAC5 Loss Impairs RB Repression of Pro-Oncogenic Genes and Confers CDK4/6 Inhibitor Resistance in Cancer
Yingke Zhou et al.
CANCER RESEARCH (2021)
Inhibiting CDK4/6 in Breast Cancer with Palbociclib, Ribociclib, and Abemaciclib: Similarities and Differences
C. Louwrens Braal et al.
DRUGS (2021)
Resistance to CDK4/6 Inhibitors in Estrogen Receptor-Positive Breast Cancer
Erin R. Scheidemann et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2021)
Deregulated Immune Pathway Associated with Palbociclib Resistance in Preclinical Breast Cancer Models: Integrative Genomics and Transcriptomics
Kamal Pandey et al.
GENES (2021)
Activation of the IFN Signaling Pathway is Associated with Resistance to CDK4/6 Inhibitors and Immune Checkpoint Activation in ER-Positive Breast Cancer
Carmine De Angelis et al.
CLINICAL CANCER RESEARCH (2021)
Phase I/II Trial of Exemestane, Ribociclib, and Everolimus in Women with HR+/HER2- Advanced Breast Cancer after Progression on CDK4/6 Inhibitors (TRINITI-1)
Aditya Bardia et al.
CLINICAL CANCER RESEARCH (2021)
Evaluation of the Association of Polymorphisms With Palbociclib-Induced Neutropenia: Pharmacogenetic Analysis of PALOMA-2/-3
Hiroji Iwata et al.
ONCOLOGIST (2021)
Co-targeting CDK4/6 and AKT with endocrine therapy prevents progression in CDK4/6 inhibitor and endocrine therapy-resistant breast cancer
Carla L. Alves et al.
NATURE COMMUNICATIONS (2021)
Clinical and Pharmacologic Differences of CDK4/6 Inhibitors in Breast Cancer
Mridula A. George et al.
FRONTIERS IN ONCOLOGY (2021)
Targeting WEE1 Inhibits Growth of Breast Cancer Cells That Are Resistant to Endocrine Therapy and CDK4/6 Inhibitors
Yassi Fallah et al.
FRONTIERS IN ONCOLOGY (2021)
Biomarker Analyses of Response to Cyclin-Dependent Kinase 4/6 Inhibition and Endocrine Therapy in Women with Treatment-Naive Metastatic Breast Cancer
Richard S. Finn et al.
CLINICAL CANCER RESEARCH (2020)
PTEN Loss Mediates Clinical Cross-Resistance to CDK4/6 and PI3Kα Inhibitors in Breast Cancer
Carlotta Costa et al.
CANCER DISCOVERY (2020)
Downregulation of miR-223 Expression Is an Early Event during Mammary Transformation and Confers Resistance to CDK4/6 Inhibitors in Luminal Breast Cancer
Francesca Citron et al.
CANCER RESEARCH (2020)
CDK4/6 inhibitor treatment for patients with hormone receptor-positive, HER2-negative, advanced or metastatic breast cancer: a US Food and Drug Administration pooled analysis
Jennifer J. Gao et al.
LANCET ONCOLOGY (2020)
The Genomic Landscape of Intrinsic and Acquired Resistance to Cyclin-Dependent Kinase 4/6 Inhibitors in Patients with Hormone Receptor-Positive Metastatic Breast Cancer
Seth A. Wander et al.
CANCER DISCOVERY (2020)
LncRNA TROJAN promotes proliferation and resistance to CDK4/6 inhibitor via CDK2 transcriptional activation in ER plus breast cancer
Xi Jin et al.
MOLECULAR CANCER (2020)
Tumour kinome re-wiring governs resistance to palbociclib in oestrogen receptor positive breast cancers, highlighting new therapeutic modalities
Sunil Pancholi et al.
ONCOGENE (2020)
Acquired FGFR and FGF Alterations Confer Resistance to Estrogen Receptor (ER) Targeted Therapy in ER+ Metastatic Breast Cancer
Pingping Mao et al.
CLINICAL CANCER RESEARCH (2020)
Abemaciclib Does Not Have a Clinically Meaningful Effect on Pharmacokinetics of CYP1A2, CYP2C9, CYP2D6, and CYP3A4 Substrates in Patients with Cancer
P. Kellie Turner et al.
DRUG METABOLISM AND DISPOSITION (2020)
Combined CDK2 and CDK4/6 Inhibition Overcomes Palbociclib Resistance in Breast Cancer by Enhancing Senescence
Kamal Pandey et al.
CANCERS (2020)
Targeting activated PI3K/mTOR signaling overcomes acquired resistance to CDK4/6-based therapies in preclinical models of hormone receptor-positive breast cancer
Neil A. O'Brien et al.
BREAST CANCER RESEARCH (2020)
Cyclin E1 Expression and Palbociclib Efficacy in Previously Treated Hormone Receptor-Positive Metastatic Breast Cancer
Nicholas C. Turner et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Direct CDKN2 Modulation of CDK4 Alters Target Engagement of CDK4 Inhibitor Drugs
Jennifer L. Green et al.
MOLECULAR CANCER THERAPEUTICS (2019)
Aberrant FGFR signaling mediates resistance to CDK4/6 inhibitors in ER plus breast cancer
Luigi Formisano et al.
NATURE COMMUNICATIONS (2019)
MicroRNA-Mediated Suppression of the TGF-β Pathway Confers Transmissible and Reversible CDK4/6 Inhibitor Resistance
Liam Cornell et al.
CELL REPORTS (2019)
Competitive interaction with keystone taxa induced negative priming under biochar amendments
Lijun Chen et al.
MICROBIOME (2019)
Overexpression of TK1 and CDK9 in plasma-derived exosomes is associated with clinical resistance to CDK4/6 inhibitors in metastatic breast cancer patients
Marzia Del Re et al.
BREAST CANCER RESEARCH AND TREATMENT (2019)
eIF4A Inhibitors Suppress Cell-Cycle Feedback Response and Acquired Resistance to CDK4/6 Inhibition in Cancer
Tim Kong et al.
MOLECULAR CANCER THERAPEUTICS (2019)
P-glycoprotein Limits Ribociclib Brain Exposure and CYP3A4 Restricts Its Oral Bioavailability
Alejandra Martinez-Chavez et al.
MOLECULAR PHARMACEUTICS (2019)
SLC36A1-mTORC1 signaling drives acquired resistance to CDK4/6 inhibitors
Akihiro Yoshida et al.
SCIENCE ADVANCES (2019)
Combined Blockade of Activating ERBB2 Mutations and ER Results in Synthetic Lethality of ER+/HER2 Mutant Breast Cancer
Sarah Croessmann et al.
CLINICAL CANCER RESEARCH (2019)
Mechanisms and Clinical Significance of Pharmacokinetic-Based Drug-Drug Interactions with Drugs Approved by the US Food and Drug Administration in 2017
Jingjing Yu et al.
DRUG METABOLISM AND DISPOSITION (2019)
Tyrosine Phosphorylation of p27Kip1 Correlates with Palbociclib Responsiveness in Breast Cancer Tumor Cells Grown in Explant Culture
Susan R. S. Gottesman et al.
MOLECULAR CANCER RESEARCH (2019)
Are all cyclin-dependent kinases 4/6 inhibitors created equal?
Antonio Marra et al.
NPJ BREAST CANCER (2019)
Multiomics Profiling Establishes the Polypharmacology of FDA-Approved CDK4/6 Inhibitors and the Potential for Differential Clinical Activity
Marc Hafner et al.
CELL CHEMICAL BIOLOGY (2019)
Ribociclib shows potential for pharmacokinetic drug-drug interactions being a substrate of ABCB1 and potent inhibitor of ABCB1, ABCG2 and CYP450 isoforms in vitro
Ales Sorf et al.
BIOCHEMICAL PHARMACOLOGY (2018)
Cyclin E overexpression confers resistance to the CDK4/6 specific inhibitor palbociclib in gastric cancer cells
Ahrum Min et al.
CANCER LETTERS (2018)
Combined c-Met/Trk Inhibition Overcomes Resistance to CDK4/6 Inhibitors in Glioblastoma
Inan Olmez et al.
CANCER RESEARCH (2018)
Different inhibitors for the same target in metastatic luminal breast cancer: is there any difference?
Elie El Rassy et al.
FUTURE ONCOLOGY (2018)
The Genetic Landscape and Clonal Evolution of Breast Cancer Resistance to Palbociclib plus Fulvestrant in the PALOMA-3 Trial
Ben O'Leary et al.
CANCER DISCOVERY (2018)
Palbociclib resistance confers dependence on an FGFR-MAP kinase-mTOR-driven pathway in KRAS-mutant non-small cell lung cancer
Eric Haines et al.
Oncotarget (2018)
Acquired palbociclib resistance in KRAS-mutant lung cancer
Charles J. Sherr
Oncotarget (2018)
Loss of the FAT1 Tumor Suppressor Promotes Resistance to CDK4/6 Inhibitors via the Hippo Pathway
Zhiqiang Li et al.
CANCER CELL (2018)
The potent and selective cyclin-dependent kinases 4 and 6 inhibitor ribociclib (LEE011) is a versatile combination partner in preclinical cancer models
Sunkyu Kim et al.
Oncotarget (2018)
Cyclin E1 and Rb modulation as common events at time of resistance to palbociclib in hormone receptor-positive breast cancer
Cristina Guarducci et al.
NPJ BREAST CANCER (2018)
Polyclonal RB1 mutations and acquired resistance to CDK 4/6 inhibitors in patients with metastatic breast cancer
R. Condorelli et al.
ANNALS OF ONCOLOGY (2018)
Physiologically Based Pharmacokinetic Modeling of Palbociclib
Yanke Yu et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2017)
Acquired CDK6 amplification promotes breast cancer resistance to CDK4/6 inhibitors and loss of ER signaling and dependence
C. Yang et al.
ONCOGENE (2017)
Challenges in assignment of allosteric effects in cytochrome P450-catalyzed substrate oxidations to structural dynamics in the hemoprotein architecture
Peter Hlavica
JOURNAL OF INORGANIC BIOCHEMISTRY (2017)
Fatal statin-Induced Rhabdomyolysis by possible Interaction with palbociclib
Kellie Lynn Nelson et al.
FRONTIERS IN ONCOLOGY (2017)
Genomic Aberrations that Activate D-type Cyclins Are Associated with Enhanced Sensitivity to the CDK4 and CDK6 Inhibitor Abemaciclib
Xueqian Gong et al.
CANCER CELL (2017)
CDK4 phosphorylation status and a linked gene expression profile predict sensitivity to palbociclib
Eric Raspe et al.
EMBO MOLECULAR MEDICINE (2017)
Kinome-Wide RNA Interference Screen Reveals a Role for PDK1 in Acquired Resistance to CDK4/6 Inhibition in ER-Positive Breast Cancer
Valerie M. Jansen et al.
CANCER RESEARCH (2017)
Effect of abemaciclib (LY2835219) on enhancement of chemotherapeutic agents in ABCB1 and ABCG2 overexpressing cells in vitro and in vivo
Tong Wu et al.
BIOCHEMICAL PHARMACOLOGY (2017)
Early Adaptation and Acquired Resistance to CDK4/6 Inhibition in Estrogen Receptor-Positive Breast Cancer
Maria Teresa Herrera-Abreu et al.
CANCER RESEARCH (2016)
Spectrum and Degree of CDK Drug Interactions Predicts Clinical Performance
Ping Chen et al.
MOLECULAR CANCER THERAPEUTICS (2016)
A gene expression signature of Retinoblastoma loss-of-function is a predictive biomarker of resistance to palbociclib in breast cancer cell lines and is prognostic in patients with ER positive early breast cancer
Luca Malorni et al.
ONCOTARGET (2016)
CDK4 Amplification Reduces Sensitivity to CDK4/6 Inhibition in Fusion-Positive Rhabdomyosarcoma
Mary E. Olanich et al.
CLINICAL CANCER RESEARCH (2015)
P-glycoprotein and breast cancer resistance protein restrict the brain penetration of the CDK4/6 inhibitor palbociclib
Mark C. de Gooijer et al.
INVESTIGATIONAL NEW DRUGS (2015)
Brain Exposure of Two Selective Dual CDK4 and CDK6 Inhibitors and the Antitumor Activity of CDK4 and CDK6 Inhibition in Combination with Temozolomide in an Intracranial Glioblastoma Xenograft
Thomas J. Raub et al.
DRUG METABOLISM AND DISPOSITION (2015)
Loss of CDKN2A expression is a frequent event in primary invasive melanoma and correlates with sensitivity to the CDK4/6 inhibitor PD0332991 in melanoma cell lines
Richard J. Young et al.
PIGMENT CELL & MELANOMA RESEARCH (2014)
Regulation of miR106b cluster through the RB pathway Mechanism and functional targets
Chellappagounder Thangavel et al.
CELL CYCLE (2013)
Impact of reducing dosing frequency on adherence to oral therapies: a literature review and meta-analysis
Kunal Srivastava et al.
PATIENT PREFERENCE AND ADHERENCE (2013)
p16-Cdk4-Rb axis controls sensitivity to a cyclin-dependent kinase inhibitor PD0332991 in glioblastoma xenograft cells
Ling Cen et al.
NEURO-ONCOLOGY (2012)
Therapeutic CDK4/6 inhibition in breast cancer: key mechanisms of response and failure
J. L. Dean et al.
ONCOGENE (2010)
Share Paper
